Patents by Inventor Dehua Huang

Dehua Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8372976
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: February 12, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Branden G. Lee, Roy Leonard Harris, III, Graziella Isabel Shevlin, Dehua Huang, Kimberly Lyn Schwarz, Garrick K. Packard, Jason Simon Parnes, Patrick William Papa, Lida Radnia Tehrani, Sophie Perrin-Ninkovic, Jennifer R. Riggs
  • Publication number: 20120289696
    Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 15, 2012
    Inventors: Nicholas D. Cosford, Thomas J. Seiders, Joseph E. Payne, Jeffrey R. Roppe, Dehua Huang, Nicholas D. Smith, Steve F. Poon, Chris King, Brian W. Eastman, Bowei Wang, Jeannie M. Arruda, Jean-Michel Vernier, Xiumin Zhao
  • Patent number: 8242143
    Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: August 14, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nicholas D. Cosford, Thomas J. Seiders, Joseph Payne, Jeffrey R. Roppe, Dehua Huang, Nicholas D. Smith, Steve F. Poon, Chris King, Brian W. Eastman, Bowei Wang, Jeannie M. Arruda, Jean-Michel Vernier, Xiumin Zhao
  • Patent number: 8082333
    Abstract: A DHCP proxy agent is provided to send on behalf of a static host a DHCP request so that an access layer security feature such as DHCP snooping/IPSG can be applied to the static host and/or in a mixed static IP and DHCP environment.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: December 20, 2011
    Assignee: Cisco Technology, Inc.
    Inventors: Dehua Huang, Premkumar Jonnala, Nagarani Chandika, Kyle Gordon Haight, Feng Zhu, Dan Mihai Florea, Bimohit Bawa
  • Publication number: 20110245245
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: June 9, 2011
    Publication date: October 6, 2011
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Branden G. Lee, Roy Leonard Harris, III, Graziella Isabel Shevlin, Dehua Huang, Kimberly Lyn Schwarz, Garrick K. Packard, Jason Simon Parnes, Patrick William Papa, Lida Radnia Tehrani, Sophie Perrin-Ninkovic, Jennifer R. Riggs
  • Publication number: 20110230526
    Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
    Type: Application
    Filed: January 28, 2011
    Publication date: September 22, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Nicholas D. Cosford, Thomas J. Seiders, Joseph E. Payne, Jeffrey R. Roppe, Dehua Huang, Nicholas D. Smith, Steve F. Poon, Chris King, Brian W. Eastman, Bowei Wang, Jeannie M. Arruda, Jean-Michel Vernier, Xiumin Zhao
  • Patent number: 7981893
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: July 19, 2011
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Branden G. Lee, Roy Leonard Harris, III, Graziella Isabel Shevlin, Dehua Huang, Kimberly Lyn Schwarz, Garrick K. Packard, Jason Simon Parnes, Patrick William Papa, Lida Radnia Tehrani, Sophie Perrin-Ninkovic, Jennifer R. Riggs
  • Patent number: 7879882
    Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nicholas D. Cosford, Thomas J. Seiders, Joseph E. Payne, Jeffrey R. Roppe, Dehua Huang, Nicholas D. Smith, Steve F. Poon, Chris King, Brian W. Eastman, Bowei Wang, Jeannie M. Arruda, Jean-Michel Vernier, Xiumin Zhao
  • Publication number: 20100121944
    Abstract: A DHCP proxy agent is provided to send on behalf of a static host a DHCP request so that an access layer security feature such as DHCP snooping/IPSG can be applied to the static host and/or in a mixed static IP and DHCP environment.
    Type: Application
    Filed: November 10, 2008
    Publication date: May 13, 2010
    Inventors: DEHUA HUANG, Premkumar Jonnala, Nagarani Chandika, Kyle Gordon Haight, Feng Zhu, Dan Mihai Florea, Bimohit Bawa
  • Patent number: 7599253
    Abstract: The invention as disclosed is of a combined acoustic pressure and acoustic vector sensor array, where multiple acoustic pressure sensors are integrated with an acoustic vector sensor in a towed array as a means of resolving the left-right ambiguity of the multiple acoustic pressure sensors.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 6, 2009
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Dehua Huang
  • Patent number: 7592337
    Abstract: Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: September 22, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Chixu Chen, Nicholas D. P. Cosford, Brian W. Eastman, Dehua Huang, Steve F. Poon, Thomas S. Reger, Jeffrey R. Roppe, Nicholas D. Smith
  • Publication number: 20090203903
    Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
    Type: Application
    Filed: October 6, 2005
    Publication date: August 13, 2009
    Inventors: Nicholas D. Cosford, Thomas J. Seiders, Joseph Payne, Jeffrey R. Roppe, Dehua Huang, Nicholas D. Smith, Steve F. Poon, Chris King, Brian W. Eastman, Bowei Wang, Jeannie M. Arruda, Jean-Michel Vernier, Xiumin Zhao
  • Patent number: 7569592
    Abstract: Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: August 4, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Chixu Chen, Brian W. Eastman, Dehua Huang, Benito Munoz, Petpiboon Prasit, Nicholas D. Smith
  • Patent number: 7551559
    Abstract: Users are allowed to specify per-interface rate limits for inter-layer binding protocol traffic. If the user-specified rate limit is exceeded on a given interface, inter-layer binding protocol messages received via that interface are caused to be dropped (e.g., by selectively dropping ILBP messages, or by simply shutting down the interface). If the rate is not exceeded, inter-layer binding protocol messages received via that interface can be validated (e.g., by comparing an inter-layer binding included in the body of an inter-layer binding protocol message to protocol status information obtained by snooping protocol messages). If the inter-layer binding does not match the protocol status information, the inter-layer binding protocol message is dropped. If a match is found, the inter-layer binding protocol message is allowed to be forwarded normally. Such systems and methods may be used to inhibit various undesirable network behavior, such as man-in-the-middle attacks.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: June 23, 2009
    Assignee: Cisco Technology, Inc.
    Inventors: Premkumar Jonnala, Adam J. Sweeney, Dehua Huang, Silviu Dobrota, Pradeep S. Sudame, Marco E. Foschiano
  • Publication number: 20090023724
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: October 18, 2007
    Publication date: January 22, 2009
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Branden G. Lee, Roy Leonard Harris, III, Graziella Isabel Shevlin, Dehua Huang, Kimberly Lyn Schwarz, Garrick K. Packard, Jason Simon Parnes, Patrick William Papa, Lida Radnia Tehrani, Sophie Perrin-Ninkovic, Jennifer R. Riggs
  • Patent number: 7462619
    Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon triple bond. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: December 9, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. Cosford, Jeffrey R. Roppe, Lida R. Tehrani, Nicholas D. Smith, Brian Stearns, Dehua Huang, Bowei Wang, Thomas J. Seiders
  • Publication number: 20080293684
    Abstract: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: July 26, 2005
    Publication date: November 27, 2008
    Inventors: Anthony B Pinkerton, Jean-Michel Vernier, Rowena V. Cube, John H. Hutchinson, Dehua Huang, Celine Bonnefous, Steven P. Govak, Theodore Kamenecka
  • Publication number: 20080167322
    Abstract: Substituted pyrazole compounds such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.
    Type: Application
    Filed: February 14, 2006
    Publication date: July 10, 2008
    Inventors: Anthony B. Pinkerton, Rowena Cube, John Hutchinson, Dehua Huang, Jean-Michel Vernier, Dong-Ming Shen
  • Patent number: 7393959
    Abstract: Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R11, R12, R13, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: July 1, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Nicholas D. P. Cosford, Dehua Huang, Jeffrey R. Roppe, Nicholas D. Smith, Lida R. Tehrani
  • Patent number: 7371767
    Abstract: Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: May 13, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Dehua Huang, Nicholas D. Smith